Evidence map›Paper›PMID 24889923›Full record

ArticleThe pharmacogenomics journal2014

A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population.

Y Vasilopoulos, C Sarri, E Zafiriou, A Patsatsi, C Stamatis, E Ntoumou, I Fassos, A Tsalta, A Karra, A Roussaki-Schulze and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. ABCB1 in dermatology: roles in skin diseases and their treatment.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Y VasilopoulosDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
C SarriDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
E ZafiriouDepartment of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa, Greece.
A PatsatsiSecond Department of Dermatology, School of Medicine, Aristotle University, Papageorgiou Hospital, Thessaloniki, Greece.
C StamatisDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
E NtoumouDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
I FassosDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
A TsaltaDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
A KarraDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
A Roussaki-SchulzeDepartment of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa, Greece.
D SotiriadisSecond Department of Dermatology, School of Medicine, Aristotle University, Papageorgiou Hospital, Thessaloniki, Greece.
Z MamurisDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
T SarafidouDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
University of Thessaly · GRPapageorgiou General Hospital · GRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis affects 2-3% of the population, causing significant morbidity and financial burden. Immunosuppressive drugs such as cyclosporine are first line systemic therapies for moderate-to-severe forms. However, patients exhibit heterogeneity in their response to therapy, possibly due to genetic factors. The aim of the present study was to assess the ABCB1 T-129C, G1199A, C1236T, G2677T and C3435T single-nucleotide polymorphisms (SNPs) as candidate predictive markers of response to cyclosporine treatment in 84 psoriasis patients. 62% of the patients were defined as responders and 38% as nonresponders. All SNPs complied with Hardy-Weinberg equilibrium. SNP and haplotype analyses were performed to access responsiveness to treatment. Association analysis revealed statistically significant association of SNP 3435 T with negative response (P=0.0075), a result that was further validated in haplotype analysis. This study is the first in the field of the pharmacogenetics of cyclosporine in psoriasis whose results merit further exploitation in larger independent cohorts.

Indexed as

AdultATP Binding Cassette Transporter, Subfamily BCyclosporineFemaleGreeceHumansMalePolymorphism, Single NucleotidePsoriasisABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BCyclosporine

Identifiers

PMID24889923
OpenAlexW2057721497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.